NS5B mutations in DAA-naïve patients | |||||
---|---|---|---|---|---|
DAAs | Genotype 1a | Fold change in EC50 | Genotype 1b | Fold change in EC50 | References |
S96Tγ | S96T | ||||
N142T | N142T | ||||
Sofosbuvir + Mericitabine | L159F | L159F (7/30, 23.3%) | Xβ | [32] | |
C223H/Y | C223H/Y | ||||
S282T | S282T | ||||
L320F | L320F | ||||
PSI-352938 | V321I (1/32, 3.1%) α | 2.0 | V321I (1/30, 3.3%) | 2.0 | |
Tegobuvir + HCV796 | C316Y/N/F/S | C316N (11/30, 36.6%) | 3.0-5.2 | ||
V362A | V362A | ||||
S365A/T | S365A/T | ||||
M414T | M414T | ||||
L419M/S | L419M/S | ||||
A421V | A421V | ||||
R422K | R422K | ||||
M423I/V/T | M423I/V/T | ||||
Filibuvir | M426L (1/32, 3.1%) | 0.8 | M426L (2/30, 6.6%) | 0.8 | [21] |
C445F | C445F | ||||
Tegobuvir | Y448H (1/32, 3.1%) | 36.0 | Y448H | [34] | |
Tegobuvir | Y452H (1/32, 3.1%) | 6.9 | Y452H (1/30, 3.3%) | 6.9 | [34] |
Tegobuvir | R465G | R465G (1/30, 3.3%) | 1.1 | [34] | |
I482L/T | I482L/T | ||||
A486V | A486V | ||||
V494A | V494A | ||||
P495A/L/S/T | P495A/L/S/T | ||||
P496A/S | P496A/S | ||||
JTK-109 + Deleobuvir | A499T | V499A (4/30, 13.3%) | 3.0 | ||
G554D | G554D | ||||
S556G/D/N | S556G/D/N | ||||
D559G/N | D559G/N |